Business
Jan 12, 2026
Not intended for UK MediaBayer bolsters development portfolio by acquisition of two investigational imaging agents (AT-01 and AT-05) from Attralus, Inc. to advance…
Jan 06, 2026
AbstractBackgroundAcquired transthyretin (ATTR) amyloidosis is increasingly reported among domino liver transplantation (DLT) recipients who receive livers from…
Jan 05, 2026
Accurate differentiation between light-chain (AL) amyloidosis and transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is critical for effective patient…
Dec 31, 2025
– NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee –– In four out of five pending patients,…
Mar 20, 2025
Advancements in RNAi Therapeutics | 2024-2025 Update for Investors in Hospitals and HealthcareRNA interference (RNAi) therapeutics have garnered significant…
Feb 25, 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting an R&D Day today in New York…
Feb 25, 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting an R&D Day today in New York…
Feb 15, 2025
CNBC’s Angelica Peebles talks to Alnylam CEO Yvonne Greenstreet about the new administration, what to expect in 2025 and the latest on their ATTR-Cardiomyopathy…
Jan 23, 2025
Alnylam Pharmaceuticals, Inc., an American company at the forefront of innovation, today received the 2024 Tell Award from Ambassador Niculin Jaeger, Consul General…
Jan 12, 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth…